DRNA News and Press, Dicerna Pharmaceuticals Inc. From 05/06/21

Dicerna Pharmaceuticals (DRNA): Q1 GAAP EPS of -$0.39 misses by $0.02.Revenue of $47.6M (+39.9% Y/Y) misses by $1.46M.Press Release For further details see: Dicerna Pharmaceuticals EPS misses by $0.02, misses on revenue

– Announced Sale of OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million; Extends Cash Runway Into 2024 – – Earned $25 Million Milestone Payment in Connection With Roche’s Initiation of GalXC™ RNAi Candidate RG...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2021 financial results aft...

Shares of Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded today at $30.19, eclipsing its 52-week high. Approximately 106,000 shares have changed hands today, as compared to an average 30-day volume of 761,000 shares. Dicerna Pharmaceuticals Inc is a biotechnology company involved in th...

Royalty Pharma (RPRX) has acquired the royalty interest of Oxlumo™ (lumasiran) from Dicerna Pharmaceuticals (DRNA) for a total consideration of up to $240M.As part of the agreement, Dicerna is entitled to receive $180M as an upfront cash payment in addition to contingent sale...

Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq...

– Dicerna To Receive $180 Million Upfront and Up to $60 Million in Potential Additional Milestone Payments – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“Dicerna”) and Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) to...

Announcing new preclinical data, Dicerna Pharmaceuticals ([[DRNA]] +3.0%) said that its GalXC-Plus™ RNAi technology had the potential to deliver a ‘deep and sustained’ messenger RNA (mRNA) knockdown against specific gene targets in the Central Nervous System.Rather than t...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technolog...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Maire Osborn, Ph.D., Associate Director of Neuro Discovery at Dicerna...